In accordance with the European Patent Convention, this patent will be granted in a total of 31 European countries of which patents for the remaining 30 countries will be forthcoming.
TAFA93, an advanced pro-drug of rapamycin is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation.
Robert Foster, chairman & CEO of Isotechnika, said: “This allows us to broaden our product pipeline while maintaining our primary focus in transplantation.”